Skip to main content
Biophytis S.A. logo

Biophytis S.A. — Investor Relations & Filings

Ticker · ALBPS ISIN · FR001400OLP5 LEI · 9695008GIE061NBGU106 PA Professional, scientific and technical activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2025-02-11 Regulatory Filings
Country FR France
Listing PA ALBPS

About Biophytis S.A.

https://www.biophytis.com/en/

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.

Recent filings

Filing Released Lang Actions
Biophytis dévoile ses perspectives stratégiques de l’année 2025
Regulatory Filings Classification · 95% confidence The document is a press release from Biophytis titled 'Biophytis dévoile ses perspectives stratégiques de l'année 2025'. It outlines the company's strategic roadmap, clinical development programs (OBA, SARA), and business partnerships. While it mentions a 'letter to shareholders' available on their website, the document itself is a corporate press release announcing these strategic updates and future outlooks. In the context of financial filings, this type of strategic communication is best classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement of business strategy and operational updates.
2025-02-11 French
Biophytis unveils its outlook strategies for 2025
Regulatory Filings Classification · 90% confidence The document is a press release from Biophytis outlining its strategic outlook for 2025, including clinical development programs and partnership updates. It functions as a general corporate announcement regarding business strategy and future initiatives. It does not fit into specific categories like financial reports, dividend announcements, or director dealings. As it is a general corporate update released via a press release format, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate announcements.
2025-02-11 English
Biophytis annonce sa participation à la conférence investisseurs BIOMED FORUM
Regulatory Filings Classification · 95% confidence The document is a press release announcing the company's participation in an upcoming investor conference (Biomed Forum). It does not contain financial results, audit reports, or specific regulatory filings, but rather serves as a general corporate announcement regarding investor relations activities. As it does not fit into more specific categories like earnings releases or reports, it falls under the general regulatory announcement category.
2025-01-27 French
Biophytis announces its participation to the BIOMED FORUM investor conference
Regulatory Filings Classification · 90% confidence The document is a press release announcing the company's participation in an upcoming investor conference (Biomed Forum). It does not contain financial results, board changes, or specific regulatory filings, but rather serves as a general corporate announcement regarding investor relations activities. As it does not fit into more specific categories like 'Investor Presentation' (which would be the slides themselves) or 'Earnings Release', it is best classified as a general regulatory filing/announcement.
2025-01-27 English
Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China
Regulatory Filings Classification · 99% confidence The document is explicitly titled "Press release" and announces a significant business event: the signing of a co-development agreement between Biophy's and AskHelpU regarding a drug candidate (BIO101) for ALS. This type of announcement, detailing strategic partnerships, clinical progress, or business milestones outside of mandatory periodic financial reporting (like 10-K or IR), is typically classified as a general corporate announcement. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific shareholder notice (like DIV or DVA), and it is not a transcript (CT) or a presentation (IP), the most appropriate category is the general Regulatory Filings (RNS) category, which serves as a broad catch-all for important, non-standard announcements, or potentially a Capital/Financing Update (CAP) if the agreement involved significant upfront payments, but the focus here is on R&D collaboration. Given the nature of a press release announcing a strategic deal, RNS is the best fit among the provided options, as it is a public disclosure of material information not covered by other specific codes. The document length (6983 chars) is substantial enough that it is not merely an announcement *of* a report, but the report itself (the press release).
2025-01-21 English
Biophytis et AskHelpU signent un accord de co-développement dans les maladies rares neuromusculaires en Chine
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces a co-development agreement between Biophy's and AskHelpU regarding a drug candidate (BIO101) for ALS in China. This type of announcement, detailing a strategic partnership, clinical development plans, and business updates, is characteristic of a general corporate announcement rather than a formal regulatory filing like a 10-K, an Earnings Release (ER), or a specific financial report (IR, AR). Since it is a press release announcing a significant business development, it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS), or potentially a Capital/Financing Update (CAP) if the agreement involved significant funding, but the primary focus here is the strategic partnership itself. Given the options, RNS serves as the best general category for non-standard, material corporate news releases that are not explicitly defined elsewhere. The document length (7781 chars) is substantial enough that it is not merely an announcement of an attachment (RPA).
2025-01-21 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.